The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Altimmune Inc. (ALT) shows that investor sentiment remained same, with the stock’s consolidated last price remained same by $0.00, or 0.00%, to $14.29. The Altimmune Inc. has recorded 7,146 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Altimmune Appoints Raymond Jordt as Chief Business Officer.
Altimmune Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $14.29 and fluctuated between $14.58 as its day high and $14.06 as its day low. The current market capitalization of Altimmune Inc. is $704.93M. A total of 0.74 million shares were traded on the day, compared to an average of 1.37M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, ALT has seen 1 BUY and 2 SELL insider trades, representing the acquisition of 139 and the disposition of 6,014 shares. Over the last 12 months, there were 24 BUYs and 21 SELLs from insiders. Insiders purchased 159,595 shares during that period but sold 204,029.
In the most recent transaction, Pisano Wayne sold 20,000 shares of ALT for 15.01 per share on Dec 22. After the transaction, the Director now owns 8,498 company shares. In a previous transaction on Aug 31, Garg Vipin K sold 20,000 shares at 20.02 per share. ALT shares that President and CEO owns now total 236,797.
Among the insiders who sold shares, Garg Vipin K disposed of 15,000 shares on Aug 12 at a per-share price of $15.06. This resulted in the President and CEO holding 259,804 shares of ALT after the transaction. In another insider transaction, Roberts M Scot sold 10,182 shares at $12.00 per share on Jul 05. Company shares held by the Chief Scientific Officer now total 8,305.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for ALT in the last 3 months, the mean price target is $27.75 with high estimates of $50.00 and low estimates of $14.00. In terms of 52-week highs and lows, ALT has a high of $23.49 and a low of $3.83.
As of this writing, ALT has an earnings estimate of -$0.5 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.44 per share and a lower estimate of -$0.57. The company reported an EPS of -$0.44 in the last quarter, which was 24.10% higher than expectations of -$0.58.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALT is Overweight with a score of 5.00. A total of 8 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.